Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
Public ClinicalTrials.gov record NCT03836352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
Study identification
- NCT ID
- NCT03836352
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 184 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 20, 2018
- Primary completion
- Dec 30, 2023
- Completion
- Dec 30, 2023
- Last update posted
- Mar 30, 2022
2018 – 2023
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 58724 | — |
| Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center | Los Angeles | California | 90048 | — |
| Boca Raton Regional Hospital, Lynn Cancer Institute | Boca Raton | Florida | 33486 | — |
| Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | 34952 | — |
| Comprehensive Hematology and Oncology | St. Petersburg | Florida | 33709 | — |
| Winship Cancer Institute: The Emory Clinic | Atlanta | Georgia | 30322 | — |
| James Brown Graham Cancer Center:University of Louisville Hospital | Louisville | Kentucky | 40202 | — |
| Ochsner Cancer Institute | New Orleans | Louisiana | 70121 | — |
| Allina Health, Virginia Piper Cancer Institute | Minneapolis | Minnesota | 55407 | — |
| Christus St. Vincent Regional Cancer Center | Santa Fe | New Mexico | 87505 | — |
| NYU Winthrop Hospital | Mineola | New York | 11501 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| University of Toledo | Toledo | Ohio | 43614 | — |
| Mary Crowley Cancer Research Center | Dallas | Texas | 75230 | — |
| MD Anderson | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03836352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2022 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03836352 live on ClinicalTrials.gov.